ETH-LAD
Clinical data | |
---|---|
Routes of administration |
Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Excretion | Renal |
Identifiers | |
|
|
Synonyms | ETH-LAD, 6-ethyl-6-nor-Lysergic acid diethylamide |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C21H27N3O |
Molar mass | 337.47 g/mol |
3D model (Jmol) | |
|
|
|
|
(what is this?) (verify) |
ETH-LAD, 6-ethyl-6-nor-lysergic acid diethylamide is an analogue of LSD. Its human psychopharmacology was first described by Alexander Shulgin in the book TiHKAL. ETH-LAD is a psychedelic drug similar to LSD, and is slightly more potent than LSD itself,[1] with an active dose reported at between 20 and 150 micrograms. ETH-LAD has subtly different effects to LSD, described as less demanding.
Legality[edit]
On June 10, 2014 the UK Advisory Council on the Misuse of Drugs (ACMD) recommended that ETH-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying it as ever having been sold or any harm associated with its use.[2] The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015 as part of The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.
ETH-LAD is illegal in Switzerland as of December 2015.[3]
Literature[edit]
- Andrew J. Hoffman, David E. Nichols: Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. In: Journal of Medicinal Chemistry. 28, 1985, p. 1252–1255, doi:10.1021/jm00147a022.
- V. J. Watts, R. B. Mailman, C. P. Lawler, K. A. Neve, D. E. Nichols: LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. In: Psychopharmacology. 118, 1995, p. 401–409, doi:10.1007/BF02245940.
- T. Niwaguchi, Y. Nakahara, H. Ishii: Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. In: Yakugaku Zasshi. Vol. 96, No. 5, May 1976, p. 673–678, PMID 987200.
- Robert C. Pfaff, Xuemei Huang, Danuta Marona-Lewicka, Robert Oberlender and David E. Nichols: Lysergamides Revisited. In: NIDA Research Monograph 146: Hallucinogens: An Update. p. 52, 1994, United States Department of Health and Human Services.
See also[edit]
References[edit]
- ^ Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–5. doi:10.1021/jm00147a022. PMID 4032428.
- ^ ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" (PDF). UK Home Office. p. 12. Retrieved 10 June 2014.
- ^ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien". Der Bundesrat.
External links[edit]
This Hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |